3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
8
Gastrointestinal
4
Gynecologic
3
Breast
3
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Dermatologic
1
Classical hematology
1
Conditions
Melanoma
5
Carcinoma, Non-Small-Cell Lung
4
Skin Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Sarcoma
2
Ovarian Neoplasms
2
Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Colonic Neoplasms
2
Carcinoma, Merkel Cell
2
Zollinger-Ellison Syndrome
1
Waldenstrom Macroglobulinemia
1
Vipoma
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Sezary Syndrome
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Mycosis Fungoides
1
Interventions
pembrolizumab
10
Nivolumab
5
Gemcitabine
4
durvalumab
3
Specimen Handling
3
Sirolimus
3
Magnetic Resonance Spectroscopy
3
Docetaxel
3
Cryosurgery
3
Cisplatin
3
Blood Specimen Collection
3
tremelimumab
2
temsirolimus
2
pertuzumab
2
pegilodecakin
2
enzalutamide
2
cabozantinib
2
alvocidib
2
Vorinostat
2
Trastuzumab
2
Ritonavir
2
Radiotherapy
2
Radiosurgery
2
Psychiatric Rehabilitation
2
Paclitaxel
2
Oxaliplatin
2
Interleukin-2
2
Cyclophosphamide
2
Carboplatin
2
Biopsy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Capecitabine
×
Dermatologic
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled